Please assess the completion status of the following clinical trial:

Trial Title: Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Documented history of migraine in the 12 months prior to screen~2. at least 4 days per month of migraine symptoms~3. \>=80% diary compliance during the Baseline period~4. Patients must be either naïve or not suitable or have failed previous migraine prophylactic treatments~Key Exclusion Criteria:~1. Older than 50 years of age at migraine onset~2. Pregnant or nursing~3. History of cluster or hemiplegic headache~4. History or evidence of major psychiatric disorder~5. Score of 19 or higher on Beck Depression Inventory (BDI)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Erenumab (Type: EXPERIMENTAL): 70 mg and 140 mg Erenumab
- Topiramate (Type: ACTIVE_COMPARATOR): Topiramate in the highest tolerated dose (50 - 100 mg/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).